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The clinical outcome of patients with breast cancer is highly variable because it not only depends on the extent of disease but also on its behaviour. Tumour cell proliferation is an important biological variable which can be regarded as an additional prognostic factor.' To date, however, methods used to assess this variable have had limited success. The methods which require labelling with 3H thymidine or its non-radioactive analogue bromodeoxyuridine,2 or disruption of cellular and tissue architecture for DNA flow cytometry,3 are complex procedures that are time consuming and can not really be applied to routine clinical samples. More recently, a monoclonal antibody Ki67 was produced. It reacts with a nuclear antigen present throughout the cell cycle of proliferating cells. 4 A major drawback to its use, however, has been the need for fresh or snap frozen material. 5 Autoantibodies from patients with systemic lupus erythematosus 
